The design and synthesis of the high efficacy, non-peptide CCK1 receptor agonist PD170292

N Bernad; B G Burgaud; D C Horwell; R A Lewthwaite; J Martinez; M C Pritchard

doi:10.1016/s0960-894x(00)00198-0

The design and synthesis of the high efficacy, non-peptide CCK1 receptor agonist PD170292

Bioorg Med Chem Lett. 2000 Jun 5;10(11):1245-8. doi: 10.1016/s0960-894x(00)00198-0.

Authors

N Bernad¹, B G Burgaud, D C Horwell, R A Lewthwaite, J Martinez, M C Pritchard

Affiliation

¹ CCIPE-Faculte de Pharmacie, Montpellier, France.

PMID: 10866391
DOI: 10.1016/s0960-894x(00)00198-0

Abstract

The design, synthesis and biological actions of a novel, non-peptide CCK1 receptor agonist (PD 170292) which exhibits a similar pharmacological profile to the CCK analogue JMV180 is reported. PD 170292 was designed based on a consideration of the structures of a peptide based CCK1 receptor selective agonist and a peptoid CCK2 receptor selective antagonist.

MeSH terms

Adamantane / analogs & derivatives*
Adamantane / chemical synthesis
Adamantane / chemistry
Adamantane / pharmacology
Animals
Citrulline / analogs & derivatives*
Citrulline / chemical synthesis
Citrulline / chemistry
Citrulline / pharmacology
Peptoids
Rats
Receptors, Cholecystokinin / agonists*

Substances

PD 170292
Peptoids
Receptors, Cholecystokinin
Citrulline
Adamantane